Impact of adjuvant taxane-based chemotherapy on development of breast cancer-related lymphedema: results from a large prospective cohort

• DOI: 10.1007/s10549-015-3408-1
• Publication Date: 2019-12-14T18:11:45Z
• Authors: Meyha N. Swaroop; Chantal M. Ferguson; Nora K. Horick; Melissa N. Skolny; Cynthia L. Miller; Lauren S. Jammallo; Cheryl L. Brunelle; Jean A. O’Toole; Steven J. Isakoff; Michelle C. Specht; Alphonse G. Taghian
• Keywords: Taxane

Taxane-based chemotherapy for the treatment of breast cancer is associated with fluid retention in extremities; however, its association development cancer-related lymphedema unclear. We sought to determine if adjuvant taxane-based increased risk or mild swelling upper extremity. 1121 patients unilateral were prospectively screened perometer measurements. Lymphedema was defined as a relative volume change (RVC) ≥10 % from preoperative baseline. Mild RVC 5- <10 %. Clinicopathologic characteristics obtained via medical record review. Kaplan–Meier and Cox proportional hazard analyses performed rates factors. 29 (324/1121) treated chemotherapy. The 2-year cumulative incidence overall cohort 5.27 By multivariate analysis, axillary lymph node dissection (ALND) (p < 0.0001), higher body mass index = 0.0007), older age at surgery 0.04) significantly lymphedema; taxane not significant when compared no non-taxane (HR 1.14, p 0.62; HR 1.56, 0.40, respectively). Chemotherapy docetaxel on analysis comparison both groups 1.63, 0.0098; 2.15, 0.02, Patients who receive are an receiving Those may experience swelling, but this does translate into subsequent lymphedema.